Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The worldwide prevalence of obesity is steadily increasing, nearly doubling between 1980 and 2008. Obesity is often associated with insulin resistance, a major risk factor for type 2 diabetes mellitus (T2DM): a costly chronic disease and serious public health problem. The underlying cause of T2DM is a failure of the beta cells of the pancreas to continue to produce enough insulin to counteract insulin resistance. Most current T2DM therapeutics do not prevent continued loss of insulin secretion capacity, and those that do have the potential to preserve beta cell mass and function are not effective in all patients. Therefore, developing new methods for preventing and treating obesity and T2DM is very timely and of great significance. There is now considerable literature demonstrating a link between inhibitory guanine nucleotide-binding protein (G protein) and G protein-coupled receptor (GPCR) signaling in insulin-responsive tissues and the pathogenesis of obesity and T2DM. These studies are suggesting new and emerging therapeutic targets for these conditions. In this review, we will discuss inhibitory G proteins and GPCRs that have primary actions in the beta cell and other peripheral sites as therapeutic targets for obesity and T2DM, improving satiety, insulin resistance and/or beta cell biology. G proteins and their receptors provide potential drug targets for treating type 2 diabetes and obesity. In a review article, a team led by Michelle Kimple of the University of Wisconsin-Madison, USA, discusses the role of guanine nucleotide-binding proteins (G proteins) and G protein-coupled receptors (GPCRs) in the pancreatic beta-cell, which secretes insulin, and in other tissues that respond to insulin. The GPCRs are a large group of membrane proteins that respond to molecules outside the cell and activate responses inside the cell. The researchers highlight several specific GPCRs that animal or human studies have indicated might be particularly suitable as therapeutic targets for diabetes or obesity. These include the EP3 receptor, the α2A adrenergic receptor, the MT2 receptor and the CB1 receptor. Further research into these proteins may yield new therapies, conclude the authors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Bouatia-Naji, N., Bonnefond, A., Cavalcanti-Proença, C., Sparsø, T., Holmkvist, J., Marchand, M., Delplanque, J., Lobbens, S., Rocheleau, G., Durand, E., et al. (2009) · Nature Genetics · doi:10.1038/ng.277 · Cited by 611
Wang, Z., & Thurmond, D. C. (2009) · Journal of Cell Science · doi:10.1242/jcs.034355 · Cited by 386
Melatonin secretion and the incidence of type 2 diabetes
McMullan, C. J., Schernhammer, E. S., Rimm, E. B., Hu, F. B., & Forman, J. P. (2013) · JAMA · doi:10.1001/jama.2013.2710 · Cited by 369
Omega-3 fatty acids and incident type 2 diabetes: A systematic review and meta-analysis
Wu, J. H. Y., Micha, R., Imamura, F., Pan, A., Biggs, M. L., Ajaz, O., Djousse, L., B. Hu, F., & Mozaffarian, D. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512001602 · Cited by 340
Kim, J. K., Michael, M. D., Previs, S. F., Peroni, O. D., Mauvais-Jarvis, F., Neschen, S., Kahn, B. B., Kahn, C. R., & Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8305 · Cited by 331
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320
Melatonin, endocrine pancreas and diabetes
Peschke, E. (2008) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2007.00519.x · Cited by 309
Cited by
Diminished mTOR signaling: a common mode of action for endocrine longevity factors
Lamming, D. W. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-735 · Cited by 71
Ramos-Romero, S., Hereu, M., Atienza, L., Casas, J., Jáuregui, O., Amézqueta, S., Dasilva, G., Medina, I., Nogués, M. R., Romeu, M., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00323.2017 · Cited by 52
“IL-6 and other inflammatory markers are elevated in obesity-induced low-grade inflammation-related IR (11, 25); ARA-derived cyclooxygenase (COX)-mediated proinflammatory factor PGE2 is the predominant prostaglandin in white AT, where it regulates adipose functions (26).”
BackgroundLi, C., Xu, M., Coyne, J., Wang, W.-B., Davila, M. L., Wang, Y., & Xiong, N. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.044 · Cited by 30
Metadata
- Authors
- Kimple, M. E., Neuman, J. C., Linnemann, A. K., & Casey, P. J.
- Venue
- Experimental & Molecular Medicine
- Published
- 2014-06-20
- Volume
- 46
- Issue
- 6
- Pages
- e102-e102
- ISSN
- 1226-3613 (ISSN-L)
- 2092-6413
- OpenAlex
- W1967031212
- Cited by
- 55
- References
- 22
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes. https://app.cochat.ai/papers/10.1038/emm.2014.40
- The paper
- Kimple, M. E., Neuman, J. C., Linnemann, A. K., & Casey, P. J. (2014). Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes. Experimental & Molecular Medicine. https://doi.org/10.1038/emm.2014.40
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.